摘要
目的从药物经济学的角度探讨过敏性鼻炎-哮喘综合征(CARAS)治疗方法的成本-效果,从而合理选择治疗药物。方法将280例CARAS患者根据药物应用的不同随机分成糖皮质激素组(A组)、抗组胺组(B组)、白三烯受体拮抗剂(C组)、抗-Ig E单克隆抗体组(D组)、转移因子组(E组)、糖皮质激素+转移因子组(F组)、糖皮质激素+抗-Ig E单克隆抗体组(G组),分别应用相应的药物治疗。结果 D,E,F组与G组的有效率均高于A,B,C组(P<0.05);C,D,F组与G组的成本明显高于A,B,E组(P<0.05);A,B组与E组的C/E值明显少于其他组(P<0.05)。结论糖皮质激素法、抗组胺法与转移因子法是治疗CARAS的最佳治疗方法。
Objective To investigate the cost effective theraPy for allergic rhinitis- asthma syndrome,from the Point of view of Pharma-ceutical economics,to choose the reasonable treatment of drug. Methods 280 cases of allergic rhinitis-astlma syndrome Patients were equally divided into glucocorticoid grouP(A),the anti histamine grouP(B),leukotriene recePtor antagonist grouP(C),anti-IgE monoclonal antibody grouP(D),transfer factor grouP(E),glucocorticoid add transfer factor grouP (F) and glucocorticoid add anti-IgE monoclonal antibody grouP(G) dePending on the drug aPPlication resPectively,each with aPProPriate medication. Results The effective rates of grouP D,E,F and G were higher than grouP A,B,C( P 〈 0. 05);the cost of grouP C,D,F and G were significantly higher than grouP A,B,E( P 〈 0. 05),the C/ E values of grouP A,B and E were significantly less than the other grouPs( P 〈 0. 05). Conclusion The method of glucocorticoid law,the anti histamine and the transfer factor are the best treatment for treating allergic rhinitis-asthma syndrome.
出处
《中国药业》
CAS
2015年第17期67-68,共2页
China Pharmaceuticals
关键词
过敏性鼻炎-哮喘综合征
成本-效果
药物经济学
糖皮质激素
抗组胺
转移因子
allergic rhinitis-asthma syndrome
cost-effectiveness
Pharmaceutical economics
glucocorticoids
anti-histamine
transfer factor